ArticleTranslational andrology and urology2026
Durable benefit in a crowded frontline landscape: final results for nivolumab-cabozantinib in metastatic renal cell carcinoma.
Gregory M Hemenway et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.